Karyopharm Marks Phase 3 Endometrial Cancer Milestone and Sees Strong Q1 Revenue Growth
Trial Enrollment Completion and Strong Financial Performance Lead 2026 Highlights
Karyopharm Therapeutics (NASDAQ: KPTI) delivered a double punch this week: the company completed patient enrollment for its pivotal Phase 3 endometrial cancer trial (XPORT-EC-042), and reported robust revenue gains for the first quarter of 2026. With topline data from its key studies expected in the coming months, the company’s trajectory this year is one to watch for both investors and the broader biotech community.
Phase 3 Clinical Milestones Set the Tone for the Year
One of the standout announcements was the completion of patient enrollment in the 257-patient Phase 3 XPORT-EC-042 trial, evaluating selinexor as a maintenance therapy for TP53 wild-type advanced/recurrent endometrial cancer. Topline data are on track for release in mid-2026, positioning Karyopharm to potentially address a clear unmet need in gynecologic oncology. Meanwhile, results from the Phase 3 SENTRY trial for myelofibrosis—a randomized study of selinexor plus ruxolitinib—were selected as a late-breaking oral presentation at the ASCO meeting, highlighting the program’s relevance for patients with rare blood cancers.
- Phase 3 XPORT-EC-042 (Endometrial Cancer): Enrollment complete; ~220 in mITT, 257 in ITT populations.
- Phase 3 SENTRY (Myelofibrosis): Met main endpoint (SVR35) at week 24; overall survival signal observed.
Revenue Growth Offset Competitive Pressure in Myeloma Franchise
Despite increasing competition in the multiple myeloma space, Karyopharm’s XPOVIO net product revenue jumped to $29.2 million from $21.1 million in the same quarter last year—a gain largely tied to improved gross-to-net adjustments and lower product returns. Total revenue for Q1 reached $35.1 million, marking an increase of $5.1 million year-over-year. Royalty revenue from international partners also showed incremental growth, hinting at continued global uptake.
| Q1 2026 | Q1 2025 |
|---|---|
| $35.07M (Total Revenue) | $30.02M |
| $29.16M (Net Product Revenue) | $21.05M |
| $1.9M (Royalty Revenue) | $1.7M |
| $91.17M (Cash, Equiv. & Restricted) | $64.10M (as of Dec 31, 2025) |
Disciplined Cost Management Narrows Quarterly Loss
On the expense side, R&D and administrative costs were tightly managed, resulting in a 20% reduction in loss from operations ($26.8M in Q1 2026 vs. $33.3M in Q1 2025). This, combined with successful financing activities, boosted the company’s cash position to $91.17 million. Looking ahead, Karyopharm reaffirmed its 2026 revenue guidance of $130 million to $150 million and expects to fund its operations into the third quarter of 2026 without the need for additional capital.
| Key Financials | Q1 2026 | Q1 2025 |
|---|---|---|
| Loss from Operations | -$26.76M | -$33.26M |
| R&D Expenses | $33.80M | $34.62M |
| SG&A Expenses | $26.68M | $27.35M |
Pivotal Year Ahead with Multiple Data Readouts
With critical data from both the SENTRY and XPORT-EC-042 trials expected in 2026, Karyopharm has positioned itself for potentially transformative regulatory and commercial milestones. Investors and stakeholders will be watching closely, especially as the company prepares for discussions with the FDA and presents at major oncology conferences such as ASCO on June 2.
What to Watch For
While Karyopharm faces ongoing commercial pressure in multiple myeloma, upcoming trial readouts in endometrial cancer and myelofibrosis could redefine the company’s growth profile. The focus now shifts to upcoming clinical data disclosures, regulatory milestones, and execution in a competitive oncology market. Given its improved financial footing and upcoming catalysts, the coming quarters may hold meaningful implications for KPTI’s future.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI